Home・Aandelen Lijst・ImmunityBio Inc

ImmunityBio Inc

Gesloten

SectorGezondheidszorg

7.73 1.71

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.6

Max

7.8100000000000005

Belangrijke statistieken
By Trading Economics
Inkomsten	-230M -863M
Verkoop	7M 51M
EPS	-0.08
Winstmarge	-1,684.596
Werknemers	684
EBITDA	378M -222M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+71.05% upside

Dividenden
By Acuity
Volgende Winsten	2 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	450M 7.9B
Vorige openingsprijs	6.02
Vorige sluitingsprijs	7.73

Nieuwssentiment

By Acuity

50%

152 / 340 Rangschikking in Healthcare

ImmunityBio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 aug 2026, 19:16 UTC

News

ImmunityBio Inc. appoints Dr. Jim Yong Kim as Vice Chairman. Shares are lower today amid broader market pressure from a U.S. jobs report.

7 aug 2026, 23:06 UTC

Immunitybio Inc's shares are lower in after-market hours, with no specific news driving the decline. The stock remains above its 20-day moving average.

6 aug 2026, 23:11 UTC

Immunitybio Inc's shares are higher in after-market trading, reflecting a slight increase since Thursday's close, though still below the 20-day moving average.

5 aug 2026, 19:26 UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4 aug 2026, 23:46 UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3 aug 2026, 23:21 UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1 aug 2026, 00:02 UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31 jul 2026, 23:06 UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30 jul 2026, 19:29 UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

29 jul 2026, 23:41 UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

28 jul 2026, 20:06 UTC

News

ImmunityBio Inc is under investigation for potential wrongdoing, contributing to its decline today. Shares remain lower since Monday's close, marking six consecutive sessions of losses.

27 jul 2026, 19:16 UTC

Immunitybio Inc. shares are lower, continuing a four-session decline amid broader market pressures and a significant drop in oil prices.

24 jul 2026, 23:06 UTC

Immunitybio Inc shares are higher in after-market hours following Friday's close, settling with a cumulative increase after earlier gains. No specific news was identified.

23 jul 2026, 09:16 UTC

Immunitybio Inc shares are higher in pre-market hours, continuing an upward trend since Wednesday. This movement occurs amid broader market pressures from disappointing tech earnings.

22 jul 2026, 19:11 UTC

Immunitybio Inc's shares are lower today, diverging from recent gains. The stock is seeing unusually high trading volume amid rising crude oil prices.

21 jul 2026, 18:06 UTC

Immunitybio Inc is trading higher during Tuesday's session amid positive market sentiment. No specific company news was identified to explain the movement.

20 jul 2026, 23:46 UTC

Immunitybio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Peer Vergelijking

Prijswijziging

ImmunityBio Inc Prognose

Koersdoel

By TipRanks

71.05% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13 USD 71.05%

Hoogste 15 USD

Laagste 12 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor ImmunityBio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan ImmunityBio Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

152 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.